Gregory W. Carter

Gregory W. Carter

Auto-generated profile, based on publicly available information

Gregory W. Carter

The Jackson Laboratory, Bar Harbor, ME, 04609, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Cell Reports
Verified
Journal Article
Open access
YWYing-Wooi Wan
Ying-Wooi Wan
RARami Al-Ouran
Rami Al-Ouran
CMCarl G. Mangleburg
Carl G. Mangleburg
TPThanneer M. Perumal
Thanneer M. Perumal
TLTom V. Lee
Tom V. Lee
BLBenjamin A. Logsdon
Benjamin A. Logsdon
We present a consensus atlas of the human brain transcriptome in Alzheimer's disease (AD), based on meta-analysis of differential gene expression in 2,114 postmortem samples. We discover 30 brain coexpression modules from seven regions as the major source of AD transcriptional perturbations. We next examine overlap with 251 brain differentially expressed gene sets from mouse models of AD and other neurodegenerative disorders. Human-mouse overlaps highlight responses to amyloid versus tau pathology and reveal age- and sex-dependent expression signatures for disease progression. Human coexpression modules enriched for neuronal and/or microglial genes broadly overlap with mouse models of AD, Huntington's disease, amyotrophic lateral sclerosis, and aging. Other human coexpression modules, including those implicated in proteostasis, are not activated in AD models but rather following other, unexpected genetic manipulations. Our results comprise a cross-species resource, highlighting transcriptional networks altered by human brain pathophysiology and identifying correspondences with mouse models for AD preclinical studies.

7 September 2015 in Epigenetics & Chromatin
Verified
Journal Article
Open access
PDF file
MWMichael Walker
Michael Walker
TBTimothy Billings
Timothy Billings
CBChristopher L. Baker
Christopher L. Baker
NPNatalie Powers
Natalie Powers
HTHui Tian
Hui Tian
PPPetko M. Petkov
Petko M. Petkov
Genetic recombination plays an important role in evolution, facilitating the creation of new, favorable combinations of alleles and the removal of deleterious mutations by unlinking them from surrounding sequences. In most mammals, the placement of genetic crossovers is determined by the binding of PRDM9, a highly polymorphic protein with a long zinc finger array, to its cognate binding sites. It is one of over 800 genes encoding proteins with zinc finger domains in the human genome. We report a novel technique, Affinity-seq, that for the first time identifies both the genome-wide binding sites of DNA-binding proteins and quantitates their relative affinities. We have applied this in vitro technique to PRDM9, the zinc-finger protein that activates genetic recombination, obtaining new information on the regulation of hotspots, whose locations and activities determine the recombination landscape. We identified 31,770 binding sites in the mouse genome for the PRDM9Dom2 variant. Comparing these results with hotspot usage in vivo, we find that less than half of potential PRDM9 binding sites are utilized in vivo. We show that hotspot usage is increased in actively transcribed genes and decreased in genomic regions containing H3K9me2/3 histone marks or bound to the nuclear lamina. These results show that a major factor determining whether a binding site will become an active hotspot and what its activity will be are constraints imposed by prior chromatin modifications on the ability of PRDM9 to bind to DNA in vivo. These constraints lead to the presence of long genomic regions depleted of recombination.

31 May 2019 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
KOKristen D. Onos
Kristen D. Onos
AUAsli Uyar
Asli Uyar
KKKelly J. Keezer
Kelly J. Keezer
HJHarriet M. Jackson
Harriet M. Jackson
CPChristoph Preuss
Christoph Preuss
GHGareth R. Howell
Gareth R. Howell
Classical laboratory strains show limited genetic diversity and do not harness natural genetic variation. Mouse models relevant to Alzheimer’s disease (AD) have largely been developed using these classical laboratory strains, such as C57BL/6J (B6), and this has likely contributed to the failure of translation of findings from mice to the clinic. Therefore, here we test the potential for natural genetic variation to enhance the translatability of AD mouse models. Two widely used AD-relevant transgenes, APPswe and PS1de9 (APP/PS1), were backcrossed from B6 to three wild-derived strains CAST/EiJ, WSB/EiJ, PWK/PhJ, representative of three Mus musculus subspecies. These new AD strains were characterized using metabolic, functional, neuropathological and transcriptional assays. Strain-, sex- and genotype-specific differences were observed in cognitive ability, neurodegeneration, plaque load, cerebrovascular health and cerebral amyloid angiopathy. Analyses of brain transcriptional data showed strain was the greatest driver of variation. We identified significant variation in myeloid cell numbers in wild type mice of different strains as well as significant differences in plaque-associated myeloid responses in APP/PS1 mice between the strains. Collectively, these data support the use of wild-derived strains to better model the complexity of human AD. Despite the rise in incidence of Alzheimer’s disease (AD), it has been over a decade since a new drug treatment has been introduced. Recently, a number of pharmaceutical giants have shut down their AD research units. One issue that these companies and researchers have struggled with is the lack of translatability of preclinical studies to the clinic. One aspect that has come under heavy scrutiny is whether the mouse can be an appropriate model for a complex human disease such as AD. Current mouse models of AD have incorporated well-known early onset AD mutations on a single genetic background, C57BL/6J, which does not develop all features of human AD- namely marked neurodegeneration. Here we sought to improve the utility and translatability of mouse models through the use of three genetically distinct, wild-derived inbred mouse strains, CAST/EiJ, WSB/EiJ and PWK/PhJ. These mice encompass millions of genetic differences that have never before been explored in the context of modeling AD. Wild-derived mice that carried the early onset AD mutations exhibited robust differences in immune response to amyloid, evidence of mixed pathology and early neurodegeneration, better recapitulating what happens in human AD than previous models.

30 January 2020 in Genes & Development
Verified
Journal Article
Open access
PDF file
CSCatrina Spruce
Catrina Spruce
SDSibongakonke Dlamini
Sibongakonke Dlamini
GAGuruprasad Ananda
Guruprasad Ananda
NBNaomi Bronkema
Naomi Bronkema
HTHui Tian
Hui Tian
CBChristopher L. Baker
Christopher L. Baker
Chromatin barriers prevent spurious interactions between regulatory elements and DNA-binding proteins. One such barrier, whose mechanism for overcoming is poorly understood, is access to recombination hot spots during meiosis. Here we show that the chromatin remodeler HELLS and DNA-binding protein PRDM9 function together to open chromatin at hot spots and provide access for the DNA double-strand break (DSB) machinery. Recombination hot spots are decorated by a unique combination of histone modifications not found at other regulatory elements. HELLS is recruited to hot spots by PRDM9 and is necessary for both histone modifications and DNA accessibility at hot spots. In male mice lacking HELLS, DSBs are retargeted to other sites of open chromatin, leading to germ cell death and sterility. Together, these data provide a model for hot spot activation in which HELLS and PRDM9 form a pioneer complex to create a unique epigenomic environment of open chromatin, permitting correct placement and repair of DSBs.

1 February 2021 in Cell Reports
Verified
Journal Article
Open access
HYHongtian Stanley Yang
Hongtian Stanley Yang
KOKristen D. Onos
Kristen D. Onos
KCKwangbom Choi
Kwangbom Choi
KKKelly J. Keezer
Kelly J. Keezer
DSDaniel A. Skelly
Daniel A. Skelly
GHGareth R. Howell
Gareth R. Howell
Genetic and genome-wide association studies suggest a central role for microglia in Alzheimer's disease (AD). However, single-cell RNA sequencing (scRNA-seq) of microglia in mice, a key preclinical model, has shown mixed results regarding translatability to human studies. To address this, scRNA-seq of microglia from C57BL/6J (B6) and wild-derived strains (WSB/EiJ, CAST/EiJ, and PWK/PhJ) with and without APP/PS1 demonstrates that genetic diversity significantly alters features and dynamics of microglia in baseline neuroimmune functions and in response to amyloidosis. Results show significant variation in the abundance of microglial subtypes or states, including numbers of previously identified disease-associated and interferon-responding microglia, across the strains. For each subtype, significant differences in the expression of many genes are observed in wild-derived strains relative to B6, including 19 genes previously associated with human AD including Apoe, Trem2, and Sorl1. This resource is critical in the development of appropriately targeted therapeutics for AD and other neurological diseases.

22 April 2024 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
GCGregory A. Cary
Gregory A. Cary
JWJesse C. Wiley
Jesse C. Wiley
JGJake Gockley
Jake Gockley
SKStephen Keegan
Stephen Keegan
SGSai Sruthi Amirtha Ganesh
Sai Sruthi Amirtha Ganesh
GCGregory W. Carter
Gregory W. Carter
INTRODUCTION: Alzheimer's disease (AD) is the predominant dementia globally, with heterogeneous presentation and penetrance of clinical symptoms, variable presence of mixed pathologies, potential disease subtypes, and numerous associated endophenotypes. Beyond the difficulty of designing treatments that address the core pathological characteristics of the disease, therapeutic development is challenged by the uncertainty of which endophenotypic areas and specific targets implicated by those endophenotypes to prioritize for further translational research. However, publicly funded consortia driving large‐scale open science efforts have produced multiple omic analyses that address both disease risk relevance and biological process involvement of genes across the genome. METHODS: Here we report the development of an informatic pipeline that draws from genetic association studies, predicted variant impact, and linkage with dementia associated phenotypes to create a genetic risk score. This is paired with a multi‐omic risk score utilizing extensive sets of both transcriptomic and proteomic studies to identify system‐level changes in expression associated with AD. These two elements combined constitute our target risk score that ranks AD risk genome‐wide. The ranked genes are organized into endophenotypic space through the development of 19 biological domains associated with AD in the described genetics and genomics studies and accompanying literature. The biological domains are constructed from exhaustive Gene Ontology (GO) term compilations, allowing automated assignment of genes into objectively defined disease‐associated biology. This rank‐and‐organize approach, performed genome‐wide, allows the characterization of aggregations of AD risk across biological domains. RESULTS: The top AD‐risk‐associated biological domains are Synapse, Immune Response, Lipid Metabolism, Mitochondrial Metabolism, Structural Stabilization, and Proteostasis, with slightly lower levels of risk enrichment present within the other 13 biological domains. DISCUSSION: This provides an objective methodology to localize risk within specific biological endophenotypes and drill down into the most significantly associated sets of GO terms and annotated genes for potential therapeutic targets.